Drug intelligence / Profile preview

escitalopram + venlafaxine + lithium

Development stage: Preclinical
Lead developer: Lundbeck
Modality: Small Molecules
Administration: Oral

Overview

A combination of three psychiatric medications used for treatment-resistant depression. Escitalopram is a selective serotonin reuptake inhibitor (SSRI), venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI), and lithium is a mood stabilizer. This combination is not a single formulated product but rather a therapeutic approach that may be used in cases where monotherapy has failed. The combination carries an increased risk of serotonin syndrome due to the enhanced serotonergic effects of all three agents.

Targets

TPH1 (Tryptophan 5-hydroxylase 1)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on escitalopram + venlafaxine + lithium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on escitalopram + venlafaxine + lithium.

Explore the full profile